CALC
CalciMedica, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.17
−1.36%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +1.2%
- EBIT
- +21.6%
- EPS
- —
- Free cash flow
- +9.8%
- Operating cash flow
- +9.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +66.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +4.5%
- Net income
- —
- EPS
- -61.5%
- Free cash flow
- -0.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026